Gopalakrishnan Maya, Kumar Ph Akhilesh, Tanwar Divya, Bhat Ks Samarth, Choudhary Bharat, Garg Mahendra K
Department of Medicine, All India Institute of Medical Sciences, Jodhpur 342005, India.
Department of Medicine, Atal Bihari Vajpayee Institute of Medical Sciences and Dr Ram Manohar Lohia Hospital, New Delhi 110001, India.
Trans R Soc Trop Med Hyg. 2025 Aug 8;119(8):943-953. doi: 10.1093/trstmh/trae111.
Snakebite is a neglected tropical disease that causes significant morbidity and mortality in India. In this study, we describe the clinical characteristics and outcomes of Echis carinatus sochureki envenoming from Western Rajasthan. We document the clinical ineffectiveness of the currently available Indian polyvalent antivenom in managing E. c. sochureki envenoming.
In this ambispective study, conducted from 14 April 2019 to 15 April 2024, we enrolled all patients presenting to our emergency department at a tertiary care centre in Jodhpur, Rajasthan, with a history of snakebite. After they provided informed consent, the demographic details, bite geo-location, bite-to-antivenom time, antivenom dose, coagulation profile, mortality and duration of hospital stay of those patients with E. c. sochureki envenoming were recorded.
Of 210 patients screened, 105 had E. c. sochureki envenoming, 103 venom-induced consumption coagulopathy, 36 (34.3%) local bleeding and 55 (52.3%) systemic bleeding. The median bite-to-antivenom time was 2 (IQR: 1.13-4.0) h. The median antivenom dose was 22 (IQR: 10-30) vials. Of 92 patients who received antivenom, 63 (68.4%) were unresponsive. Total antivenom dose and geographical location (West zone) were significant predictors of antivenom unresponsiveness. Fifty-three of 70 patients (75.7%) had delayed hypofibrinogenaemia. The mean hospital stay was 8.3±7.1 d with nine (8.6%) mortalities.
Our study highlights the alarming finding of poor antivenom response to E. c. sochureki envenoming, with significant clinical bleeding and delayed coagulopathy. There is an urgent need for region-specific antivenom in Western India.
蛇咬伤是一种被忽视的热带疾病,在印度导致了严重的发病率和死亡率。在本研究中,我们描述了来自拉贾斯坦邦西部的锯鳞蝰蛇(Echis carinatus sochureki)咬伤的临床特征和结局。我们记录了目前可用的印度多价抗蛇毒血清在治疗锯鳞蝰蛇咬伤方面的临床无效性。
在这项于2019年4月14日至2024年4月15日进行的前瞻性研究中,我们纳入了所有前往拉贾斯坦邦焦特布尔一家三级护理中心急诊科就诊且有蛇咬伤史的患者。在他们提供知情同意后,记录了锯鳞蝰蛇咬伤患者的人口统计学细节、咬伤地理位置、咬伤至使用抗蛇毒血清的时间、抗蛇毒血清剂量、凝血指标、死亡率和住院时间。
在筛查的210例患者中,105例为锯鳞蝰蛇咬伤,103例出现毒液诱导的消耗性凝血病,36例(34.3%)出现局部出血,55例(52.3%)出现全身出血。咬伤至使用抗蛇毒血清的中位时间为2(四分位间距:1.13 - 4.0)小时。抗蛇毒血清的中位剂量为22(四分位间距:10 - 30)瓶。在92例接受抗蛇毒血清治疗的患者中,63例(68.4%)无反应。抗蛇毒血清总剂量和地理位置(西区)是抗蛇毒血清无反应的重要预测因素。70例患者中有53例(75.7%)出现延迟性低纤维蛋白原血症。平均住院时间为8.3±7.1天,9例(8.6%)死亡。
我们的研究突出了令人担忧的发现,即抗蛇毒血清对锯鳞蝰蛇咬伤反应不佳,伴有严重的临床出血和延迟性凝血病。印度西部迫切需要针对该地区的抗蛇毒血清。